<DOC>
	<DOCNO>NCT00745719</DOCNO>
	<brief_summary>To test hypothesis total parathyroidectomy retard cardiovascular calcification , improve bone mineral density , reduce cardiac hypertrophy arterial stiffen end-stage renal disease patient maintenance dialysis .</brief_summary>
	<brief_title>Parathyroidectomy Endstage Renal Disease</brief_title>
	<detailed_description>Secondary hyperparathyroidism ( SHPT ) patient end-stage renal disease contributes increase cardiovascular morbidity mortality via different mechanism . Uncontrolled hyperparathyroidism associate leave ventricular hypertrophy implicate development cardiac interstitial fibrosis diastolic dysfunction .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Endstage renal disease patient receive either longterm hemodialysis peritoneal dialysis treatment , elevate intact parathyroid hormone ( iPTH ) level &gt; 500pg/ml two occasion . Patients parathyroid nodular diffuse hyperplasia identify ultrasound image radioisotope scan . Patients provide inform consent study . Patients significant background valvular heart disease Patients unfit general anaesthesia Patients acute myocardial infarction within recent two month Patients poor general condition Patients plan live relate kidney transplant within 1 year Patients previous history parathyroidectomy Patients calciphylaxis Patients underlie active malignancy Patients contraindication MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>parathyroidectomy</keyword>
	<keyword>cardiovascular</keyword>
	<keyword>bone</keyword>
	<keyword>endstage renal disease</keyword>
</DOC>